

Heart Failure With Preserved Ejection Fraction In Persp

Circulation Research

124, 1598-1617

DOI: [10.1161/circresaha.119.313572](https://doi.org/10.1161/circresaha.119.313572)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Response by Pfeffer et al to Letter Regarding Article, "Heart Failure With Preserved Ejection Fraction in Perspective" Circulation Research, 2019, 125, e26.	4.5	3
2	Package delivered, but message not received. Heart, 2019, 105, 1528-1529.	2.9	1
3	Letter by Nikolova et al Regarding Article, "Heart Failure With Preserved Ejection Fraction in Perspective" Circulation Research, 2019, 125, e24-e25.	4.5	1
4	The Medical and Device-Related Treatment of Heart Failure. Circulation Research, 2019, 124, 1519-1519.	4.5	8
5	Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2539-2550.	2.8	69
6	The "Bslc2" Mouse. JACC Basic To Translational Science, 2019, 4, 938-939.	4.1	0
7	Sector-wise golden-angle phase contrast with high temporal resolution for evaluation of left ventricular diastolic dysfunction. Magnetic Resonance in Medicine, 2020, 83, 1310-1321.	3.0	15
8	Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2020, 22, 489-498.	7.1	92
9	Left atrial myopathy in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2020, 22, 486-488.	7.1	9
10	Sudden cardiac death risk prediction in heart failure with preserved ejection fraction. Heart Rhythm, 2020, 17, 358-364.	0.7	31
11	Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard. European Journal of Heart Failure, 2020, 22, 422-424.	7.1	9
12	The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model. Scientific Reports, 2020, 10, 15701.	3.3	8
13	Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1506.	7.4	27
14	Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease. JACC Basic To Translational Science, 2020, 5, 916-927.	4.1	17
15	Heart failure with preserved ejection fraction in Belgium: characteristics and outcome of a real-life cohort. Acta Cardiologica, 2021, 76, 697-706.	0.9	6
16	Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. Cardiovascular Diagnosis and Therapy, 2020, 10, 1580-1603.	1.7	35
17	Acute decompensated heart failure in a non cardiology tertiary referral centre, Sarawak General Hospital (SGH-HF). BMC Cardiovascular Disorders, 2020, 20, 511.	1.7	8
18	Pulmonary Vascular Pressures and Gas Exchange Response to Exercise in Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2020, 26, 1011-1015.	1.7	1

#	ARTICLE	IF	CITATIONS
19	Cardiac Magnetic Resonance to Enhance Phenotypic Characterization of HFpEF. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2129-2131.	5.3	0
20	Trends in cause-specific readmissions in heart failure with preserved vs. reduced and mid-range ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2894-2903.	3.1	13
21	Lipid in the midst of metabolic remodeling – Therapeutic implications for the failing heart. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 120-132.	13.7	14
22	Cardiac Contractility Modulation in Heart Failure: Mechanisms and Clinical Evidence. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.9	1
23	Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2020, 26, 919-928.	1.7	10
24	Comprehensive Cardiovascular Magnetic Resonance Diastolic Dysfunction Grading Shows Very Good Agreement Compared With Echocardiography. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2530-2542.	5.3	19
25	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. <i>EMBO Molecular Medicine</i> , 2020, 12, e10865.	6.9	104
26	Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6742.	4.1	19
27	Identification of physiologic treatment targets with favourable haemodynamic consequences in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 3685-3693.	3.1	9
28	Addressing the sudden cardiac death conundrum in heart failure with preserved ejection fraction: do we need a microscope or a telescope?. <i>European Journal of Heart Failure</i> , 2020, 22, 1930-1932.	7.1	2
29	Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e016760.	3.7	19
30	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. <i>Circulation</i> , 2020, 142, 1725-1735.	1.6	77
31	Investigating Circadian Heart Rate Variability in Coronary Artery Disease Patients with Various Degrees of Left Ventricle Ejection Fraction. , 2020, 2020, 714-717.		4
32	Oxidative Stress and Inflammatory Modulation of Ca ²⁺ Handling in Metabolic HFpEF-Related Left Atrial Cardiomyopathy. <i>Antioxidants</i> , 2020, 9, 860.	5.1	17
33	Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism. <i>ESC Heart Failure</i> , 2020, 7, 4061-4070.	3.1	10
34	Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 849-863.	2.6	188
35	<p>Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations<p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 769-785.	2.0	16
36	Systemic Action of Inflammatory Mediators in Patients with Essential Hypertension and Diastolic Chronic Heart Failure: A Clinical Pathophysiological Study. <i>Pathophysiology</i> , 2020, 27, 30-43.	2.2	2

#	ARTICLE	IF	CITATIONS
37	T1-Mapping and extracellular volume estimates in pediatric subjects with Duchenne muscular dystrophy and healthy controls at 3T. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 85.	3.3	9
38	Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2817-2829.	2.8	40
39	Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Endocrinology</i> , 2020, 11, 558271.	3.5	18
40	Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction. <i>Circulation: Heart Failure</i> , 2020, 13, e006609.	3.9	23
41	Epidemiology of heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1342-1356.	7.1	948
42	Potential use of ubiquinol and d-ribose in patients with heart failure with preserved ejection fraction. <i>Annals of Medicine and Surgery</i> , 2020, 55, 77-80.	1.1	5
43	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	4.1	17
44	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. <i>Circulation</i> , 2020, 142, 230-243.	1.6	59
45	Hypertension and heart failure: focus on high-risk populations. <i>Current Opinion in Cardiology</i> , 2020, 35, 381-388.	1.8	2
46	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. <i>International Journal of Cardiology</i> , 2020, 316, 172-179.	1.7	15
47	Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. <i>JACC: Heart Failure</i> , 2020, 8, 640-653.	4.1	65
48	Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 654-656.	4.1	5
49	Evaluation and management of heart failure with preserved ejection fraction. <i>Nature Reviews Cardiology</i> , 2020, 17, 559-573.	13.7	339
50	Association of renal resistance index and arterial stiffness on clinical outcomes in patients with mild-to-moderate renal dysfunction and presence or absence of heart failure with preserved ejection fraction. <i>Heart and Vessels</i> , 2020, 35, 1699-1708.	1.2	6
51	Mitochondrial Dysfunction and Inflammaging in Heart Failure: Novel Roles of CYP-Derived Epoxy lipids. <i>Cells</i> , 2020, 9, 1565.	4.1	28
52	Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics. <i>Cardiovascular Pathology</i> , 2020, 49, 107243.	1.6	12
53	Reply. <i>JACC: Heart Failure</i> , 2020, 8, 597-598.	4.1	0
54	Targeting Age-Related Pathways in Heart Failure. <i>Circulation Research</i> , 2020, 126, 533-551.	4.5	111

#	ARTICLE	IF	CITATIONS
55	Hypertension and heart failure: insights from exercise stress testing. <i>European Journal of Heart Failure</i> , 2020, 22, 469-471.	7.1	4
56	Beta-blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve-HR trial). <i>Clinical Cardiology</i> , 2020, 43, 423-429.	1.8	18
57	Gender differences in the impact of health literacy on hospital readmission among older heart failure patients: A prospective cohort study. <i>Journal of Advanced Nursing</i> , 2020, 76, 1345-1354.	3.3	15
58	Echocardiographic parameters differentiating heart failure with preserved ejection fraction from asymptomatic left ventricular diastolic dysfunction. <i>Echocardiography</i> , 2020, 37, 247-252.	0.9	7
59	Female Heart Health: Is GPER the Missing Link?. <i>Frontiers in Endocrinology</i> , 2019, 10, 919.	3.5	30
60	A Novel Cardioprotective Therapy That Also Improves Glycemia. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1349.	7.4	1
61	Heart Failure With Preserved Ejection Fraction: Where Do We Stand?. <i>Mayo Clinic Proceedings</i> , 2020, 95, 629-631.	3.0	2
62	Caring experiences of family caregivers of patients with heart failure: A meta-ethnographic review of the past 10 years. <i>European Journal of Cardiovascular Nursing</i> , 2020, 19, 473-485.	0.9	20
63	Perspectives in the Treatment of Heart Failure with Preserved Ejection Fraction: From Drugs to Devices. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 266-271.	2.1	0
64	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1501-1502.	2.8	0
65	The Role of Adipose Triglyceride Lipase and Cytosolic Lipolysis in Cardiac Function and Heart Failure. <i>Cell Reports Medicine</i> , 2020, 1, 100001.	6.5	27
66	Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. <i>Cardiovascular Research</i> , 2021, 117, 43-59.	3.8	72
67	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 1839-1859.	1.3	30
68	Estimating Left Ventricle Ejection Fraction Levels Using Circadian Heart Rate Variability Features and Support Vector Regression Models. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2021, 25, 746-754.	6.3	23
69	Impaired global longitudinal strain in elderly patients with preserved ejection fraction is associated with raised post-exercise left ventricular filling pressure. <i>Journal of Echocardiography</i> , 2021, 19, 37-44.	0.8	2
70	The clinical characteristics and outcomes of heart failure patient with chronic obstructive pulmonary disease from the Japanese community-based registry. <i>Heart and Vessels</i> , 2021, 36, 223-234.	1.2	3
71	Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology. <i>Cardiovascular Research</i> , 2021, 117, 999-1014.	3.8	47
72	Metabolic inflammation in heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 423-434.	3.8	102

#	ARTICLE	IF	CITATIONS
73	Deficit of glucocorticoid-induced leucine zipper amplifies angiotensin-induced cardiomyocyte hypertrophy and diastolic dysfunction. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 217-228.	3.6	7
74	SGLT2-inhibitors; more than just glycosuria and diuresis. <i>Heart Failure Reviews</i> , 2021, 26, 623-642.	3.9	41
75	Factors contributing to energy loss in left ventricle during diastolic and systolic phases in elderly patients. <i>Echocardiography</i> , 2021, 38, 72-80.	0.9	2
76	The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 443-450.	1.2	19
77	Psychological stress in heart failure: a potentially actionable disease modifier. <i>Heart Failure Reviews</i> , 2021, 26, 561-575.	3.9	9
78	Cardiovascular Autonomic Disturbances in Heart Failure With Preserved Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 609-620.	1.7	22
79	Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care system. <i>Postgraduate Medicine</i> , 2021, 133, 140-145.	2.0	8
80	Fighting HFpEF in women: taking aim at belly fat. <i>European Heart Journal</i> , 2021, 42, 1606-1608.	2.2	8
81	Plasma amino acid metabolomic pattern in heart failure patients with either preserved or reduced ejection fraction: The relation to established risk variables and prognosis. <i>Biomedical Chromatography</i> , 2021, 35, e5012.	1.7	6
82	Sex-specific associations of obesity with exercise capacity and diastolic function in Koreans. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 254-262.	2.6	9
83	Complex and Potentially Harmful Medication Patterns in Heart Failure with Preserved Ejection Fraction. <i>American Journal of Medicine</i> , 2021, 134, 374-382.	1.5	14
84	Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	12
85	Extracardiac Abnormalities of Preload Reserve. <i>Circulation: Heart Failure</i> , 2021, 14, e007308.	3.9	33
86	Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 104.	1.7	5
87	Pregnancy Associated Heart Failure With Preserved Ejection Fraction: Risk Factors and Maternal Morbidity. <i>Journal of Cardiac Failure</i> , 2021, 27, 143-152.	1.7	14
88	Newly Identified Tricks From an Old Dog. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 362-364.	5.3	0
89	Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans. <i>Clinical Cardiology</i> , 2021, 44, 646-655.	1.8	17
90	Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction. <i>Nature Communications</i> , 2021, 12, 1684.	12.8	59

#	ARTICLE	IF	CITATIONS
91	Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps. <i>Journal of the American Heart Association</i> , 2021, 10, e017684.	3.7	10
92	Vitamin D and Cardiovascular Disease: An Updated Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2896.	4.1	56
93	Invasive Hemodynamic and Metabolic Evaluation of HFpEF. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.9	7
94	Exercise Training for Heart Failure With Preserved Ejection Fraction (ExTraMATCH III): Protocol for an Individual Patient Data Meta-Analysis. <i>Bioengineered</i> , 2021, 10, 3-11.	3.2	0
95	Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?. <i>Current Opinion in Cardiology</i> , 2021, 36, 413-419.	1.8	12
97	ASSESSMENT OF MYOCARDIAL LEFT VENTRICULAR FUNCTIONS USING 2D SPECKLE TRACKING IN NORMAL PREGNANT FEMALES IN COMPARISON TO NORMAL NON-PREGNANT FEMALES. <i>Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar</i> , 2021, 50, 1231-1242.	0.1	0
98	Impact of a pharmacist-based multidimensional intervention aimed at decreasing the risk of hyperkalemia in heart failure patients: A Latin-American experience. <i>International Journal of Cardiology</i> , 2021, 329, 136-143.	1.7	2
99	Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 678530.	2.4	6
100	Real-Time Cardiac Magnetic Resonance Imaging. <i>Circulation</i> , 2021, 143, 1499-1501.	1.6	3
101	Estimated Glomerular Filtration Rate Is Associated With an Increased Risk of Death in Heart Failure Patients With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 643358.	2.4	3
102	Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure. <i>Circulation</i> , 2021, 143, 1377-1390.	1.6	223
103	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. <i>Clinical Science</i> , 2021, 135, 991-1007.	4.3	18
104	Mast Cells Are the Trigger of Small Vessel Disease and Diastolic Dysfunction in Diabetic Obese Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e193-e207.	2.4	11
105	Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 455-464.	2.8	5
106	Diastolic dysfunction in women with ischemia and no obstructive coronary artery disease: Mechanistic insight from magnetic resonance imaging. <i>International Journal of Cardiology</i> , 2021, 331, 1-7.	1.7	8
107	Outcomes among acute heart failure emergency department patients by preserved vs. reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2889-2898.	3.1	7
108	Right ventricular diastolic dysfunction and failure: a review. <i>Heart Failure Reviews</i> , 2022, 27, 1077-1090.	3.9	6
109	Clinical and Genetic Analysis of KATP Variants With Heart Failure Risk in Patients With Decreased Serum ApoA-I Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2264-2278.	3.6	5

#	ARTICLE	IF	CITATIONS
110	Age-related alterations in cardiac and arterial structure and function in hypertensive women and men. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1322-1334.	2.0	11
111	Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1233-1243.	1.8	16
112	A new scoring system for predicting short-term outcomes in Chinese patients with critically ill acute decompensated heart failure. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 228.	1.7	2
113	S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction. <i>Circulation</i> , 2021, 143, 1912-1925.	1.6	28
114	Salutary Acute Effects of Exercise on Central Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021, 27, 1313-1320.	1.7	5
115	Falla cardiaca con fracci3n de eyecci3n preservada: generalidades y aproximaci3n en el perioperatorio. <i>Revista Med</i> , 2021, 28, 49-60.	0.1	0
116	Menopausal symptoms and risk of heart failure: a retrospective analysis from Taiwan National Health Insurance Database. <i>ESC Heart Failure</i> , 2021, 8, 3295-3307.	3.1	5
118	Cardiopulmonary Pathophysiological Aspects in the Context of COVID-19 and Obesity. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1848-1857.	0.6	1
119	Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 1648-1658.	7.1	64
120	Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 123.	6.8	9
121	Relationships Between Objectively Measured Physical Activity, Exercise Capacity, and Quality of Life in Older Patients With Obese Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021, 27, 635-641.	1.7	8
122	Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Pharmacology</i> , 2021, 12, 646240.	3.5	20
123	A Porcine Model of Heart Failure With Preserved Ejection Fraction Induced by Chronic Pressure Overload Characterized by Cardiac Fibrosis and Remodeling. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 677727.	2.4	12
124	Invasive Hemodynamics in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 415-422.	2.1	3
125	Exercise intolerance in volume overload heart failure is associated with low carotid body mediated chemoreflex drive. <i>Scientific Reports</i> , 2021, 11, 14458.	3.3	1
126	Skeletal Muscle Microvascular Dysfunction Manifests Early in Diabetic Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715400.	2.4	5
127	Pathophysiology of Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 327-335.	2.1	16
128	Stress Testing in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 435-445.	2.1	2

#	ARTICLE	IF	CITATIONS
129	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7650.	4.1	17
130	Phenomapping for classification of doxorubicin-induced cardiomyopathy in rats. <i>Toxicology and Applied Pharmacology</i> , 2021, 423, 115579.	2.8	5
131	Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 315-326.	2.1	18
132	Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 463-482.	2.1	4
133	Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108822.	2.8	4
134	Defining cardiac involvement in idiopathic inflammatory myopathies: a systematic review. <i>Rheumatology</i> , 2021, 61, 103-120.	1.9	17
135	Heart Failure with Preserved Ejection Fraction: Current Opinion and Future Perspectives. <i>Heart Failure Clinics</i> , 2021, 17, xiii-xiv.	2.1	3
136	Valvular Disease and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 387-395.	2.1	5
137	Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?. <i>European Heart Journal</i> , 2021, 42, 3753-3755.	2.2	9
138	Artificial Intelligence to Diagnose Heart Failure Based on Chest X-Rays and Potential Clinical Implications. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1153-1155.	1.7	3
139	Diuretic Resistance Treated with Low-Dose Hydralazine: A Case Report and Review of the Literature. <i>Case Reports in Nephrology and Dialysis</i> , 2021, 11, 254-260.	0.6	0
140	Novel Non-pharmaceutical Advancements in Heart Failure Management: The Emerging Role of Technology. <i>Current Cardiology Reviews</i> , 2022, 18, .	1.5	1
141	Left Atrial Dimension to Left Ventricle Ejection Fraction Ratio Can Predict Long-Term Major Adverse Events In Patients With Acute Coronary Syndrome. <i>Harran Üniversitesi Tıp Fakültesi Dergisi</i> , 2021, 18, 329-335.	0.3	0
142	Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study. <i>Cancer</i> , 2021, 127, 4646-4655.	4.1	10
143	Prognostic Impact of Echocardiographic Diastolic Dysfunction on Outcomes in Patients With Heart Failure With Preserved Ejection Fraction—Insights From the PURSUIT-HFpEF Registry. <i>Circulation Journal</i> , 2021, 86, 23-33.	1.6	9
144	Heart Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 695952.	2.4	13
145	Diagnosis and Management of Cirrhotic Cardiomyopathy. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 186-199.	0.9	19
146	The Potential Therapeutic Role of Celastrol in Patients With Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 725602.	2.4	0

#	ARTICLE	IF	CITATIONS
147	Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. <i>European Heart Journal</i> , 2021, 42, 4420-4430.	2.2	65
148	Optimizing the discovery and assessment of therapeutic targets in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3643-3655.	3.1	5
149	What Is the Status of Regenerative Therapy in Heart Failure?. <i>Current Cardiology Reports</i> , 2021, 23, 146.	2.9	4
150	Iron therapy in iron-deficiency patients with heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2021, 100, e26919.	1.0	1
151	Mechanisms of sodium-mediated injury in cardiovascular disease: old play, new scripts. <i>FEBS Journal</i> , 2022, 289, 7260-7273.	4.7	7
152	Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. <i>Annual Review of Medicine</i> , 2022, 73, 321-337.	12.2	52
153	Exercise training reduces brainstem oxidative stress and restores normal breathing function in heart failure. <i>Free Radical Biology and Medicine</i> , 2021, 172, 470-481.	2.9	9
154	Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 772-795.	4.1	24
155	Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction. <i>Experimental Biology and Medicine</i> , 2021, 246, 2511-2521.	2.4	9
156	Trends in Heart Failure Hospitalizations in the US from 2008 to 2018. <i>Journal of Cardiac Failure</i> , 2022, 28, 171-180.	1.7	40
157	Stearoyl-CoA Desaturase (SCD) Induces Cardiac Dysfunction with Cardiac Lipid Overload and Angiotensin II AT1 Receptor Protein Up-Regulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9883.	4.1	6
158	Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1166-1187.	2.8	87
159	Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-23.	4.0	7
160	Effects of angiotensin-receptor neprilysin inhibitor on exercise capacity, quality of life, and cardiac function in heart failure with preserved ejection fraction. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 2, e0160.	0.1	0
161	Bariatric surgery decreases the number of future hospital admissions for diastolic heart failure in subjects with severe obesity: a retrospective analysis of the US National Inpatient Sample database. <i>Surgery for Obesity and Related Diseases</i> , 2022, 18, 1-8.	1.2	6
162	Autonomic regulation device therapy in patients with heart failure with preserved ejection fraction. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 2, e0150.	0.1	0
163	Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology. <i>Journal of the American Heart Association</i> , 2021, 10, e021584.	3.7	12
164	Association of coronary microvascular dysfunction and cardiac bridge integrator 1, a cardiomyocyte dysfunction biomarker. <i>Clinical Cardiology</i> , 2021, 44, 1586-1593.	1.8	2

#	ARTICLE	IF	CITATIONS
165	Predominance of Heart Failure With Preserved Ejection Fraction in Postmenopausal Women: Intra- and Extra-Cardiomyocyte Maladaptive Alterations Scaffolded by Estrogen Deficiency. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 685996.	3.7	13
166	Risk prediction model of in-hospital mortality in heart failure with preserved ejection fraction and mid-range ejection fraction: a retrospective cohort study. <i>Biomarkers in Medicine</i> , 2021, 15, 1223-1232.	1.4	1
167	Intrarenal modulation of NF- κ B activity attenuates cardiac injury in a swine model of CKD: a renal-cardio axis. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, F411-F423.	2.7	9
168	Chronic GPR30 agonist therapy causes restoration of normal cardiac functional performance in a male mouse model of progressive heart failure: Insights into cellular mechanisms. <i>Life Sciences</i> , 2021, 285, 119955.	4.3	8
169	Evaluation of patients with heart failure. , 2022, , 51-76.		0
170	Quantification of Biventricular Myocardial Strain Using CMR Feature Tracking: Reproducibility in Small Animals. <i>BioMed Research International</i> , 2021, 2021, 1-14.	1.9	2
171	Clinical Phenotypes and Age-Related Differences in Presentation, Treatment, and Outcome of Heart Failure with Preserved Ejection Fraction: A Vietnamese Multicenter Research. <i>Cardiology Research and Practice</i> , 2021, 2021, 1-9.	1.1	5
172	Heart failure with preserved ejection fraction, atrial fibrillation, and increased NT-proBNP levels. <i>Herz</i> , 2021, 46, 191-197.	1.1	4
173	Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. <i>Journal of Cardiac Failure</i> , 2020, 26, 876-884.	1.7	4
174	The Control of Diastolic Calcium in the Heart. <i>Circulation Research</i> , 2020, 126, 395-412.	4.5	94
175	Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction. <i>Cardiac Failure Review</i> , 2020, 6, e27.	3.0	7
176	Heart failure with preserved ejection fraction: insights from recent clinical researches. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 514-534.	1.7	10
178	Association of the H ₂ FPEF Risk Score with Recurrence of Atrial Fibrillation Following Pulmonary Vein Isolation. <i>Journal of Atrial Fibrillation</i> , 2020, 12, 2295.	0.5	4
179	Heart Failure with Preserved Ejection Fraction: the Major Unmet Need in Cardiology. <i>Korean Circulation Journal</i> , 2020, 50, 1051.	1.9	15
180	Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. <i>World Journal of Cardiology</i> , 2020, 12, 7-25.	1.5	28
181	Coding proposal on phenotyping heart failure with preserved ejection fraction: A practical tool for facilitating etiology-oriented therapy. <i>Cardiology Journal</i> , 2020, 27, 97-98.	1.2	18
183	Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction. <i>Circulation Journal</i> , 2023, 87, 1039-1046.	1.6	6
184	Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 2, e0162.	0.1	0

#	ARTICLE	IF	CITATIONS
185	Association Between Inflammation, Incident Heart Failure, and Heart Failure Subtypes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2023, 75, 1036-1045.	3.4	8
186	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008293.	3.9	18
187	Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2021, 345, 68-76.	1.7	12
190	RISK STRATIFICATION AND PROGNOSTIC MARKERS IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE. , 2020, , 1-4.		0
191	Humanistic burden and economic impact of heart failure – a systematic review of the literature. <i>F1000Research</i> , 0, 8, 859.	1.6	6
192	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. <i>Nature Medicine</i> , 2021, 27, 1954-1960.	30.7	299
193	Blood Differential Gene Expression in Patients with Chronic Heart Failure and Systemic Iron Deficiency: Pathways Involved in Pathophysiology and Impact on Clinical Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 4937.	2.4	6
194	Comparison of Efficacy of Ivabradine With Traditional Therapy in Patients With Left Ventricular Dysfunction. <i>Cureus</i> , 2021, 13, e19192.	0.5	0
195	Do patients with heart failure and preserved, mid-range or reduced ejection fraction have different outcomes?. <i>Cor Et Vasa</i> , 2020, 62, 567-573.	0.1	1
196	Skeletal muscle (dys)function in heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2021, 36, 219-226.	1.8	2
198	Construction and analysis of a joint diagnosis model of random forest and artificial neural network for heart failure. <i>Aging</i> , 2020, 12, 26221-26235.	3.1	38
199	Combined Effect of Elevated Blood Pressure and Obesity on Left Ventricular Diastolic Function. <i>Cardiometabolic Syndrome Journal</i> , 2022, 2, 39.	0.6	2
200	Research Progress of Heart Failure with Preserved Ejection Fraction. <i>Advances in Clinical Medicine</i> , 2021, 11, 4831-4840.	0.0	0
201	New Insights into Heart Failure: From the Beginning to Now. , 2021, , 231-241.		0
202	Sleep-disordered breathing patterns in hospitalized patients with acute heart failure across the entire spectrum of ejection fraction. <i>Sleep and Breathing</i> , 2021, , 1.	1.7	1
203	Heart failure in the elderly. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 219-232.	0.2	3
204	Acute heart failure in elderly patients: a review of invasive and non-invasive management. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 560-576.	0.2	0
205	Age-related changes in clinical characteristics and outcomes of chronic heart failure outpatients in a cardiology setting. A report from the Italian Network on Heart Failure. <i>International Journal of Cardiology</i> , 2022, 346, 36-44.	1.7	6

#	ARTICLE	IF	CITATIONS
207	Chronic Kidney Disease and Heart Failure—Everyday Diagnostic Challenges. <i>Diagnostics</i> , 2021, 11, 2164.	2.6	6
208	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022, 346, 19-26.	1.7	2
209	Skeletal myopathy in a rat model of postmenopausal heart failure with preserved ejection fraction. <i>Journal of Applied Physiology</i> , 2022, 132, 106-125.	2.5	4
210	Left atrial volume index to left ventricular ejection fraction ratio predicted major adverse cardiovascular event in ST-Elevated myocardial infarction patients during 8 years of follow-up. <i>Journal of Cardiovascular Echography</i> , 2021, 31, 227.	0.4	0
211	A Practical Approach to Differential Diagnosis of Cardiomyopathies with Infiltrative Phenotypes. , 2021, 1, 132-138.		0
212	Chronische Herzinsuffizienz: Selten isoliert, daher fordernd. , 0, , .		0
213	Prediction of LVEF using BiLSTM and Swarm Decomposition-based 24-h HRV Components. , 2021, , .		0
215	Identification of patients with preclinical heart failure with preserved ejection fraction using the H2FPEF score. , 2022, 1, 59-66.		6
216	Heart failure with preserved ejection fraction: Squaring the circle between comorbidities and cardiovascular abnormalities. <i>European Journal of Internal Medicine</i> , 2022, 99, 1-6.	2.2	5
217	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	2.6	5
218	Left Atrial Circulatory Assistance in Simulated Diastolic Heart Failure Model: First in Vitro and in Vivo. <i>Journal of Cardiac Failure</i> , 2022, , .	1.7	4
219	Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 829151.	2.4	4
220	A G-protein-biased S1P1 agonist, SAR247799, improved LVH and diastolic function in a rat model of metabolic syndrome. <i>PLoS ONE</i> , 2022, 17, e0257929.	2.5	3
221	Real-time radial tagging for quantification of left ventricular torsion. <i>Magnetic Resonance in Medicine</i> , 2022, , .	3.0	0
222	Treatment of heart failure with a preserved ejection fraction. <i>Journal of the Korean Medical Association</i> , 2022, 65, 18-25.	0.3	0
223	SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction. <i>Drugs and Aging</i> , 2022, 39, 185-190.	2.7	4
224	The Value of Echocardiography Combined with NT-pro BNP Level in Assessment and Prognosis of Diastolic Heart Failure. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-8.	1.3	2
225	Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension. <i>Hypertension Research</i> , 2022, 45, 292-307.	2.7	12

#	ARTICLE	IF	CITATIONS
226	Validation of Noninvasive Remote Dielectric Sensing System to Quantify Lung Fluid Levels. <i>Journal of Clinical Medicine</i> , 2022, 11, 164.	2.4	22
228	Qualitative and Quantitative Effects of Fatty Acids Involved in Heart Diseases. <i>Metabolites</i> , 2022, 12, 210.	2.9	6
229	Heart failure and catheter ablation of atrial fibrillation: Navigating the difficult waters of heart failure phenotypes. <i>European Journal of Internal Medicine</i> , 2022, 99, 13-18.	2.2	2
230	Age and Sex Differences in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Aging</i> , 2022, 3, .	2.6	4
231	Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients. <i>JACC Basic To Translational Science</i> , 2022, 7, 116-127.	4.1	20
232	Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts. <i>Scientific Reports</i> , 2022, 12, 4760.	3.3	1
233	An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	2.6	3
234	Prognostic value of functional capacity after transitional rehabilitation in older patients hospitalized for heart failure. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1774-1784.	2.6	4
235	The Cardiomyocyte in Heart Failure with Preserved Ejection Fractionâ€”Victim of Its Environment?. <i>Cells</i> , 2022, 11, 867.	4.1	1
236	Ellagic acid prevents myocardial infarction-induced left ventricular diastolic dysfunction in ovariectomized rats. <i>Journal of Nutritional Biochemistry</i> , 2022, 105, 108990.	4.2	4
237	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1148-1153.	7.1	11
238	Advances in Multimodality Cardiovascular Imaging in the Diagnosis of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 758975.	2.4	8
239	Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors. <i>JACC: CardioOncology</i> , 2022, 4, 53-65.	4.0	16
240	Targeting the vasculature in cardiometabolic disease. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	18
241	Cell Therapy in Heart Failure with Preserved Ejection Fraction. <i>Cardiac Failure Review</i> , 2022, 8, e08.	3.0	3
242	Short-Chain Carbon Sources. <i>JACC Basic To Translational Science</i> , 2022, 7, 730-742.	4.1	8
243	Malnutrition as a factor aggravating the heart failure course in the elderly and senile age. <i>Russian Journal of Cardiology</i> , 2022, 27, 4583.	1.4	3
244	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <sc>HOMAGE</sc> and the <sc>UK</sc> Biobank. <i>European Journal of Heart Failure</i> , 2022, 24, 976-984.	7.1	5

#	ARTICLE	IF	CITATIONS
245	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 1016-1030.	1.7	5
246	The Emerging Role of FUNDC1-Mediated Mitophagy in Cardiovascular Diseases. <i>Frontiers in Physiology</i> , 2021, 12, 807654.	2.8	16
247	Heart failure with preserved ejection fraction: will we ever all agree?. <i>British Journal of Cardiac Nursing</i> , 2021, 16, 1-3.	0.1	0
248	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2021, 100, e28448.	1.0	2
251	Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study. <i>European Heart Journal</i> , 2022, 43, 2196-2208.	2.2	12
252	Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, , .	4.1	2
253	Effect of β -blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction. <i>Bulletin of Siberian Medicine</i> , 2022, 21, 35-46.	0.3	0
254	Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 854501.	2.4	9
255	Editorial: Role of Molecular Modulators in Combatting Cardiac Injury and Disease: Prevention, Repair and Regeneration. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 861442.	2.4	0
256	Potential Role of the Retrotrapezoid Nucleus in Mediating Cardio-Respiratory Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 2022, 13, 863963.	2.8	2
259	Impact of Diabetic Retinopathy on Prognosis of Patients with Heart Failure with Preserved Ejection Fraction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	2.6	0
260	Blood Pressure Variability and Heart Failure Hospitalization: Results From the Women's Health Initiative. <i>American Journal of Preventive Medicine</i> , 2022, 63, 410-418.	3.0	4
261	Pediatric Diastolic Heart Failure: Clinical Features Description of 421 Cases. <i>Frontiers in Pediatrics</i> , 2022, 10, 846408.	1.9	5
262	Improving the Characterization of Stage A and B Heart Failure by Adding Global Longitudinal Strain. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1380-1387.	5.3	8
263	New therapies for the treatment of heart failure with preserved ejection fraction. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1424-1430.	1.0	4
264	New insights into the potential utility of the left atrial function analysis in heart failure with preserved ejection fraction diagnosis. <i>PLoS ONE</i> , 2022, 17, e0267962.	2.5	4
265	Guideline-Directed Cardiac Devices for Patients with Heart Failure. <i>American Journal of Nursing</i> , 2022, Published Ahead of Print, .	0.4	0
266	Estimation of Functional Aerobic Capacity Using the Sit-to-Stand Test in Older Adults with Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2022, 11, 2692.	2.4	5

#	ARTICLE	IF	CITATIONS
267	Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease. <i>Circulation Research</i> , 2022, 130, 1382-1403.	4.5	13
268	Mechanical and interventional support for heart failure with preserved ejection fraction: A review. <i>Artificial Organs</i> , 2022, , .	1.9	1
269	Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models. <i>JACC Basic To Translational Science</i> , 2022, 7, 844-857.	4.1	11
270	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2186-2199.	2.9	9
271	Prognostic Value of the MAGGIC Score, H2FPEF Score, and HFA-PEFF Algorithm in Patients with Exertional Dyspnea and the Incremental Value of Exercise Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 966-975.	2.8	7
272	Understanding the Role of SERCA2a Microdomain Remodeling in Heart Failure Induced by Obesity and Type 2 Diabetes. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 163.	1.6	4
273	The sST2 level is an independent influencing factor associated with atrial fibrillation in heart failure patients: a case-control study. <i>Journal of Thoracic Disease</i> , 2022, 14, 1578-1587.	1.4	6
274	Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELPS registry. <i>European Journal of Heart Failure</i> , 2022, 24, 1493-1503.	7.1	22
275	Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. <i>Journal of Molecular Medicine</i> , 2022, 100, 875-901.	3.9	8
276	Life-Years Lost After Newly Diagnosed Atrial Fibrillation in Patients with Heart Failure. <i>Clinical Epidemiology</i> , 0, Volume 14, 711-720.	3.0	0
277	p53-Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	9
278	Demand for Mechanical Circulatory Support. , 2022, , 63-77.		0
279	Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations. <i>Cardiology Journal</i> , 0, , .	1.2	3
280	Comorbidities in heart failure with preserved ejection fraction. <i>Herz</i> , 2022, 47, 301-307.	1.1	10
281	Intermittent Fasting as Possible Treatment for Heart Failure. <i>Current Vascular Pharmacology</i> , 2022, 20, 260-271.	1.7	5
282	Exercise haemodynamics in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2022, 9, 3079-3091.	3.1	13
283	Má»† LIÄŠN QUAN Glá»†A Äá»~ Cá»†NG NHÄ" TRÄ† TRÄŠN SIÄŠU Ä,M Vá»†šI CHá»†C NÄ,NG NHÄ" TRÄ† VÄ€ NT-PROBNP á»ž Bá»†NH NHÄ, PHÄ,N SUá†T Tá»†NG MÄU Bá»†O Tá»†N. <i>Y Hoc Viet Nam</i> , 2022, 515, .	0.0	0
284	The Clinical Problem of Pelvic Venous Disorders. <i>Interventional Cardiology Clinics</i> , 2022, 11, 307-324.	0.4	1

#	ARTICLE	IF	CITATIONS
285	Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, .	1.8	8
286	A Novel Composite Indicator of Predicting Mortality Risk for Heart Failure Patients With Diabetes Admitted to Intensive Care Unit Based on Machine Learning. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	3
287	Remodeling of Retinal Arterioles and Carotid Arteries in Heart Failure Development—A Preliminary Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3721.	2.4	2
288	Caloric restriction-mimetics for the reduction of heart failure risk in aging heart: with consideration of gender-related differences. <i>Military Medical Research</i> , 2022, 9, .	3.4	3
289	A Data Mining-Based Study on Medication Rules of Chinese Herbs to Treat Heart Failure with Preserved Ejection Fraction. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 847-854.	1.6	8
290	Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction. <i>European Journal of Pharmacology</i> , 2022, 929, 175126.	3.5	16
291	Sex Differences in Cardiomyopathy. <i>Current Cardiovascular Risk Reports</i> , 0, , .	2.0	0
292	Systems Pharmacology-Based Strategy to Investigate Pharmacological Mechanisms of Total Flavonoids in <i>Dracocephalum moldavica</i> on Chronic Heart Failure. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8409.	4.1	4
293	Heart failure with preserved ejection fraction: A mini review. , 2022, 6, 005-006.		0
294	Arrhythmic Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction: Mechanisms, Genetics, and Future Directions. <i>CJC Open</i> , 2022, 4, 959-969.	1.5	3
295	Understanding heart failure with preserved ejection fraction. <i>Independent Nurse</i> , 2022, 2022, 22-25.	0.1	0
296	Cardiac micro-RNA and transcriptomic profile of a novel swine model of chronic kidney disease and left ventricular diastolic dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 323, H659-H669.	3.2	5
298	Prognostic implications of coronary artery disease and stress tests in patients with elevated left ventricular filling pressure and preserved ejection fraction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
299	Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review. <i>Revista Portuguesa De Cardiologia</i> , 2022, 41, 865-885.	0.5	4
300	Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 256.	1.6	8
301	Coronary Artery Disease and Heart Failure With Preserved Ejection Fraction: The ARIC Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	12
302	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. <i>IJC Heart and Vasculature</i> , 2022, 42, 101103.	1.1	4
303	The diagnostic value of peroxisome proliferator-activated receptor- γ coactivator-1 α in identifying different chronic heart failure phenotypes. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	0

#	ARTICLE	IF	CITATIONS
304	Novidades e Reflexões sobre o Tratamento Farmacológico da Insuficiência Cardíaca com Fração de Ejeção Preservada. Arquivos Brasileiros De Cardiologia, 2022, , .	0.8	0
305	Calcium-Dependent Signaling in Cardiac Myocytes. , 2022, , 3-37.		0
307	Characterization of left atrial assist device implantation: Early results of ex vivo anatomical assessment. Artificial Organs, 0, , .	1.9	1
308	Protective Effect of Natural Medicinal Plants on Cardiomyocyte Injury in Heart Failure: Targeting the Dysregulation of Mitochondrial Homeostasis and Mitophagy. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-24.	4.0	1
309	Association of endothelial glycocalyx shedding and coronary microcirculation assessed by an angiography-derived index of microcirculatory resistance in patients with suspected coronary artery disease. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
310	NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction. Antioxidants, 2022, 11, 1822.	5.1	14
311	SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	6
313	Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes. Advances in Therapy, 2022, 39, 4837-4846.	2.9	5
314	Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction. Current Heart Failure Reports, 2022, 19, 445-457.	3.3	1
315	Current Status of Dapagliflozin in Congestive Heart Failure. Cureus, 2022, , .	0.5	0
316	Therapeutic potential of HDAC inhibitors in the treatment of cardiac diseases: A short review. Current Drug Targets, 2022, 23, .	2.1	1
317	Device Therapy for Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 507-515.	2.2	5
318	Acetylation and phosphorylation changes to cardiac proteins in experimental HFpEF due to metabolic risk reveal targets for treatment. Life Sciences, 2022, 309, 120998.	4.3	4
319	The Role of Multimodality Imaging in the Evaluation of Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 443-457.	2.2	2
320	Hemodynamic Assessment in Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 459-472.	2.2	2
321	Mitochondrial oxidative stress contributes to diastolic dysfunction through impaired mitochondrial dynamics. Redox Biology, 2022, 57, 102474.	9.0	13
322	Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. Cardiac Failure Review, 0, 8, .	3.0	2
323	SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes. Circulation Research, 2022, 131, 926-943.	4.5	18

#	ARTICLE	IF	CITATIONS
325	Identification of energy metabolism-related biomarkers for risk prediction of heart failure patients using random forest algorithm. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	4
326	Angiotensin, vascular endothelial growth factors and secretory phospholipase A2 in heart failure patients with preserved ejection fraction. <i>European Journal of Internal Medicine</i> , 2022, 106, 111-119.	2.2	6
327	Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study. <i>ESC Heart Failure</i> , 2023, 10, 322-333.	3.1	3
328	Non-invasive assessment of HFpEF in mouse models: current gaps and future directions. <i>BMC Medicine</i> , 2022, 20, .	5.5	5
329	Construction and analysis of heart failure diagnosis model based on random forest and artificial neural network. <i>Medicine (United States)</i> , 2022, 101, e31097.	1.0	2
330	Identification of key pharmacodynamic markers of American ginseng against heart failure based on metabolomics and zebrafish model. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	5
331	Efficacy of Xinbao pill on chronic heart failure: Study protocol of a multicenter, randomized, double-blind, placebo-controlled trial. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	0
332	Antiquated ejection fraction: Basic research applications for speckle tracking echocardiography. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	3
333	Transcriptomic profile analysis of the left atrium in spontaneously hypertensive rats in the early stage. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
334	Dapagliflozin and Spironolactone Improved Clinical Symptoms and CV Outcomes in Patient with HF Preserved Ejection Fraction (HFpEF) in Hard-to-Reach Rural African Population: A Case Series. <i>Case Reports in Clinical Medicine</i> , 2022, 11, 465-473.	0.2	0
335	Insulin-like Growth Factor-1 and Myocardial Remodeling in Patients with Chronic Heart Failure of Ischemic Origin. <i>Rational Pharmacotherapy in Cardiology</i> , 2022, 18, 564-570.	0.8	0
336	The predictive value of changes in left atrial volume index for rehospitalization in heart failure with preserved ejection fraction. <i>Clinical Cardiology</i> , 2023, 46, 151-158.	1.8	2
337	Predictors of early heart failure rehospitalization among older adults with preserved and reduced ejection fraction: A review and derivation of a conceptual model. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2023, 58, 125-133.	1.6	0
338	Medical Therapy for Heart Failure with Preserved Ejection Fraction. <i>Methodist DeBakey Cardiovascular Journal</i> , 2022, 18, 17-26.	1.0	1
339	Cardiac Contractility Modulation as a Novel Therapy for Patients with Heart Failure. <i>Lecture Notes in Bioengineering</i> , 2022, , 81-92.	0.4	0
340	Prognostic implications of elevated pulmonary artery systolic pressure on 6-month mortality in elderly patients with acute myocardial infarction. , 2022, 2, 197-202.		2
341	Systemic Delivery of Extracellular Vesicles Attenuates Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Clinical Electrophysiology</i> , 2023, 9, 147-158.	3.2	6
342	Comparative Analysis of Non-Coding RNA Transcriptomics in Heart Failure. <i>Biomedicines</i> , 2022, 10, 3076.	3.2	5

#	ARTICLE	IF	CITATIONS
343	Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews. <i>International Journal of Cardiology</i> , 2022, , .	1.7	1
344	Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea. <i>European Journal of Heart Failure</i> , 2023, 25, 185-196.	7.1	23
345	Insight Ventilation Perfusion Inefficiency in Patients With Heart Failure With Preserved Ejection Fraction. <i>Chest</i> , 2022, 162, 1233-1235.	0.8	1
346	Managing Diastolic Dysfunction Perioperatively. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 0, , 108925322211424.	1.0	1
347	Systems Biology in Chronic Heart Failure—Identification of Potential miRNA Regulators. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15226.	4.1	7
348	Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2023, 81, 460-473.	2.8	20
349	Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2
350	Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	1.7	2
351	Genetic Association between Polymorphisms of Interleukin-32 and Dilated Cardiomyopathy in Chinese Han Population. <i>Disease Markers</i> , 2022, 2022, 1-9.	1.3	0
352	Clinical Modelling of RVHF Using Pre-Operative Variables: A Direct and Inverse Feature Extraction Technique. <i>Diagnostics</i> , 2022, 12, 3061.	2.6	5
353	Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. <i>ESC Heart Failure</i> , 2023, 10, 1555-1569.	3.1	3
354	GPR30 Alleviates Pressure Overload-Induced Myocardial Hypertrophy in Ovariectomized Mice by Regulating Autophagy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 904.	4.1	1
355	Role of Î²-blockers in Preventing Heart Failure and Major Adverse Cardiac Events Post Myocardial Infarction. <i>Current Cardiology Reviews</i> , 2023, 19, .	1.5	1
356	Avanços na abordagem terapêutica da insuficiência cardíaca com fração de ejeção preservada (ICFEP): O uso de inibidores de SGLT-2. <i>Brazilian Journal of Health Review</i> , 2023, 6, 286-300.	0.1	0
357	Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	6
358	Insulin resistance and heart failure with preserved ejection fraction. Pathogenetic and therapeutic crossroads. <i>Diabetes Mellitus</i> , 2023, 25, 535-547.	1.9	0
359	Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis. <i>Cardiology in Review</i> , 2024, 32, 114-123.	1.4	4
360	New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside— and Back. <i>Biomedicines</i> , 2023, 11, 70.	3.2	1

#	ARTICLE	IF	CITATIONS
361	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	11
362	Integrins in Cardiac Form, Function, and Disease. <i>Biology of Extracellular Matrix</i> , 2023, , 135-183.	0.3	0
363	Inhibition of transglutaminase 2 (TG2) ameliorates ventricular fibrosis in isoproterenol-induced heart failure in rats. <i>Life Sciences</i> , 2023, 321, 121564.	4.3	2
364	Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction. <i>European Journal of Heart Failure</i> , 2023, 25, 657-668.	7.1	14
365	Renal Denervation Helps Preserve the Ejection Fraction by Preserving Endocardial-Endothelial Function during Heart Failure. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7302.	4.1	1
366	A review of cardio-pulmonary microvascular dysfunction in pulmonary hypertension. <i>American Heart Journal Plus</i> , 2023, 26, 100255.	0.6	0
367	Fecal microbiome transplantation and tributyrin improves early cardiac dysfunction and modifies the BCAA metabolic pathway in a diet induced pre-HFpEF mouse model. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	2
368	Functional outcome after cardiac rehabilitation and its association with survival in heart failure across the spectrum of ejection fraction. <i>European Journal of Internal Medicine</i> , 2023, 110, 86-92.	2.2	2
369	Machine learning approach to stratify complex heterogeneity of chronic heart failure: A report from the CHARTâ€² study. <i>ESC Heart Failure</i> , 2023, 10, 1597-1604.	3.1	4
370	Cardiac amyloidosis: a significant blind spot of the H2FPEF score. <i>Panminerva Medica</i> , 0, , .	0.8	0
371	The association between patterns of early respiratory disease and diastolic dysfunction in preterm infants. <i>Journal of Perinatology</i> , 2023, 43, 1268-1273.	2.0	2
372	The Prevalence and Risk Factors of Chronic Heart Failure in the Mongolian Population. <i>Diagnostics</i> , 2023, 13, 999.	2.6	0
373	Markers for predicting the efficacy of beta-blockers in vasovagal syncope management in children: A mini-review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
374	All-Cause and Cardiovascular-Related Mortality in CKD Patients With and Without Heart Failure: A Population-Based Cohort Study in Kaiser Permanente Southern California. <i>Kidney Medicine</i> , 2023, 5, 100624.	2.0	2
375	Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2023, 324, H739-H750.	3.2	2
376	The potential of dynamic 99mTc-sestamibi cadmium zinc telluride-single-photon emission computed tomography camera assessing myocardial flow reserve in patients with heart failure with preserved ejection fraction. <i>European Heart Journal Open</i> , 2023, 3, .	2.3	0
377	Cyclocreatine Phosphate: A Novel Bioenergetic/Anti-Inflammatory Drug That Resuscitates Poorly Functioning Hearts and Protects against Development of Heart Failure. <i>Pharmaceuticals</i> , 2023, 16, 453.	3.8	1
378	Mice with endothelial cellâ€²selective adhesion molecule deficiency develop coronary microvascular rarefaction and left ventricle diastolic dysfunction. <i>Physiological Reports</i> , 2023, 11, .	1.7	2

#	ARTICLE	IF	CITATIONS
379	Management of patients with heart failure and preserved ejection fraction. <i>Heart</i> , 2023, 109, 874-883.	2.9	9
380	Evaluation of large animal models for preclinical studies of heart failure with preserved ejection fraction using clinical score systems. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	0
381	Heart Failure with Preserved Ejection Fraction. , 2023, , 89-106.		0
382	Imaging in Heart Failure with Preserved Ejection Fraction: A Multimodality Imaging Point of View. <i>Cardiac Failure Review</i> , 0, 9, .	3.0	1
383	Impact of concomitant mitral valve surgery on the clinical outcomes of patients with moderate functional mitral regurgitation and HFpEF undergoing aortic valve replacement: a cohort study. <i>Journal of Cardiothoracic Surgery</i> , 2023, 18, .	1.1	0
384	Genetic Variation in Intercellular Adhesion Molecule-1 (ICAM-1) and Diastolic Heart Failure in the Black Population in the USA. <i>Journal of Cardiac Failure</i> , 2023, , .	1.7	0
385	Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1810-1834.	2.8	61
386	Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1. <i>Circulation: Heart Failure</i> , 2023, 16, .	3.9	2
387	Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. <i>Circulation: Heart Failure</i> , 2023, 16, .	3.9	8
388	Association of left ventricular strainâ€‘volume loop characteristics with adverse events in patients with heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 1168-1176.	1.2	2
389	Heart Failure With Preserved Ejection Fraction: Current Status of Daily Clinical Practice in Indonesia. <i>Cureus</i> , 2023, , .	0.5	0
390	The prognostic value of <sc>CHA₂</sc><sc>DS₂</sc>â€‘VASC</sc> and <sc>modifiedâ€‘CHADS₂</sc></sc> scores for cardiovascular events in diabetics and nonâ€‘diabetics haemodialysis patients. <i>Nephrology</i> , 2023, 28, 387-398.	1.6	1
391	Catestatin Protects Against Diastolic Dysfunction by Attenuating Mitochondrial Reactive Oxygen Species Generation. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	0
392	Patient Perspectives on the Burden of Heart Failure with Preserved Ejection Fraction in a US Commercially Insured and Medicare Advantage Population: A Survey Study. <i>Patient Preference and Adherence</i> , 0, Volume 17, 1181-1196.	1.8	0
393	Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
394	Changes in cardiac time intervals over a decade and the risk of incident heart failure: The Copenhagen City Heart Study. <i>International Journal of Cardiology</i> , 2023, 386, 141-148.	1.7	0
395	Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. <i>JACC: Heart Failure</i> , 2023, 11, 1380-1393.	4.1	3
396	Association between the beta-blockers, calcium channel blockers, allâ€‘cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. <i>Clinical Cardiology</i> , 2023, 46, 845-852.	1.8	1

#	ARTICLE	IF	CITATIONS
397	Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews. <i>Heart Failure Reviews</i> , 2023, 28, 1033-1051.	3.9	2
398	Imaging Early Life Cardiovascular Phenotype. <i>Circulation Research</i> , 2023, 132, 1607-1627.	4.5	1
399	Filling gaps in female gout: a cross-sectional study of comorbidities in 192 037 hospitalised patients. <i>RMD Open</i> , 2023, 9, e003191.	3.8	3
400	Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta-analysis. <i>ESC Heart Failure</i> , 2023, 10, 2225-2235.	3.1	0
401	Targeting epicardial adipose tissue: A potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 0, 14, 724-740.	3.5	1
402	Evaluation the value of H ₂ FPEF score and HFA-PEFF step E score in the diagnosis of heart failure with preserved ejection fraction. <i>Acta Cardiologica</i> , 0, , 1-6.	0.9	3
403	Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases. <i>Cells</i> , 2023, 12, 1629.	4.1	6
404	Projected clinical benefits of dapagliflozin in patients with heart failure with preserved ejection fraction. <i>Future Cardiology</i> , 2023, 19, 333-342.	1.2	5
405	Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	2.7	1
406	Depressed myocardial cross-bridge cycling kinetics in a female guinea pig model of diastolic heart failure. <i>Journal of General Physiology</i> , 2023, 155, .	1.9	0
407	Personalized Management for Heart Failure with Preserved Ejection Fraction. <i>Journal of Personalized Medicine</i> , 2023, 13, 746.	2.5	2
408	Pathological mechanism of heart failure with preserved ejection fraction in rats based on iTRAQ technology. <i>PeerJ</i> , 0, 11, e15280.	2.0	1
409	Clinical effect of Danshen decoction in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2023, 18, e0284877.	2.5	8
410	Longitudinal Changes in Left Ventricular Diastolic Function in Late Life. <i>JACC: Cardiovascular Imaging</i> , 2023, 16, 1133-1145.	5.3	3
411	Cardiovascular responses to static handgrip exercise and postexercise ischemia in heart failure with preserved ejection fraction. <i>Journal of Applied Physiology</i> , 2023, 134, 1508-1519.	2.5	1
412	Angiotensin-converting enzyme inhibitory peptide attenuates cardiac hypertrophy associated with ACE2/Ang (1-7)/MasR axis and PKC β 1 pathway. <i>Journal of Functional Foods</i> , 2023, 105, 105570.	3.4	2
413	Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	1
414	Stem Cells in Heart Failure: Future Perspective. , 2023, , 491-514.		0

#	ARTICLE	IF	CITATIONS
415	Positive Airway Pressure Therapy Adherence and Health Care Resource Use in Patients With Obstructive Sleep Apnea and Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	8
416	A Systematic Critical Appraisal of Clinical Practice Guidelines in Heart Failure Using the AGREE II Tool. <i>American Journal of Cardiology</i> , 2023, 202, 192-198.	1.6	2
417	Diastolic dysfunction of ventricles in patients with calcium pyrophosphate crystal deposition disease while receiving anti-inflammatory therapy. <i>Terapevticheskii Arkhiv</i> , 2023, 95, 386-391.	0.8	0
418	A network medicine approach to study comorbidities in heart failure with preserved ejection fraction. <i>BMC Medicine</i> , 2023, 21, .	5.5	1
419	Left Ventricular Gene Expression in Heart Failure With Preserved Ejection Fraction—Profibrotic and Proinflammatory Pathways and Genes. <i>Circulation: Heart Failure</i> , 0, , .	3.9	2
420	Inhibition of protein arginine deiminase 4 prevents inflammation-mediated heart failure in arthritis. <i>Life Science Alliance</i> , 2023, 6, e202302055.	2.8	1
421	Diastology with Cardiac MRI: A Practical Guide. <i>Radiographics</i> , 2023, 43, .	3.3	0
422	Symptomatic Heart Failure With Preserved Ejection Fraction: Is It Too Late to Consider Additional Therapies?. <i>Journal of Cardiac Failure</i> , 2023, , .	1.7	0
423	Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial. <i>Circulation</i> , 2023, 148, 834-844.	1.6	8
424	Value of the HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the inflammatory myopathy population. <i>Arthritis Research and Therapy</i> , 2023, 25, .	3.5	0
425	State-of-the-art methodologies used in preclinical studies to assess left ventricular diastolic and systolic function in mice, pitfalls and troubleshooting. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	0
426	WarpPINN: Cine-MR image registration with physics-informed neural networks. <i>Medical Image Analysis</i> , 2023, 89, 102925.	11.6	2
427	Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2023, , .	4.1	1
428	A novel polygenic risk score improves prognostic prediction of heart failure with preserved ejection fraction in the Chinese Han population. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1382-1390.	1.8	3
429	Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14292.	4.1	1
430	Commonalities and differences in carotid body dysfunction in hypertension and heart failure. <i>Journal of Physiology</i> , 2023, 601, 5527-5551.	2.9	2
431	Computational modeling of ventricular-ventricular interactions suggest a role in clinical conditions involving heart failure. <i>Frontiers in Physiology</i> , 0, 14, .	2.8	0
432	The prevalence of cardiorenal anemia syndrome among patients with heart failure and its association with all-cause hospitalizations: a retrospective single-center study from the Middle East. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	0

#	ARTICLE	IF	CITATIONS
433	Recent successes in heart failure treatment. <i>Nature Medicine</i> , 2023, 29, 2424-2437.	30.7	4
434	Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	0
435	The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Annals of Pharmacotherapy</i> , 2024, 58, 506-513.	1.9	0
436	Cardiac magnetic resonance left ventricular filling pressure is linked to symptoms, signs and prognosis in heart failure. <i>ESC Heart Failure</i> , 2023, 10, 3067-3076.	3.1	0
437	Decoding molecular signature on heart of septic mice with distinct left ventricular ejection fraction. <i>IScience</i> , 2023, 26, 107825.	4.1	0
438	Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2023, 148, 1165-1178.	1.6	6
439	Neural control of the circulation during exercise in heart failure with reduced and preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2023, 325, H998-H1011.	3.2	0
440	Heart Failure: Recent Advances and Breakthroughs. <i>Disease-a-Month</i> , 2024, 70, 101634.	1.1	0
441	A Narrative Review on the Efficacy and Safety of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction. <i>Cureus</i> , 2023, , .	0.5	0
442	O Escore de Selvester QRS é um Preditor de Mortalidade na Insuficiência Cardíaca com Fração de Ejeção Preservada. <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.8	0
443	Association Between Coronary Artery Calcium Score and Left Ventricular Diastolic Dysfunction in Patients with Hypertension. , 0, 2, .		0
444	New phenotype of a patient with heart failure and «supra-normal left ventricular ejection fraction». <i>Kardiologicheskii Vestnik</i> , 2023, 18, 16.	0.4	0
445	Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction. <i>Current Problems in Cardiology</i> , 2024, 49, 102127.	2.4	0
446	Part I: <sc>PSAP Live</sc>: Updates from 2022 <sc>Book</sc> 1 (<sc><i>Cardiology</i></sc>). <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2023, 6, 1163-1169.	1.0	0
447	Heart Failure with Preserved Ejection Fraction in Brazil: A Systematic Review. , 2023, 3, .		0
448	Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry. <i>Heart</i> , 2024, 110, 359-365.	2.9	1
449	Quantitative characteristics of cardiomyopathy phenotypes in children and adults by the value of deviation from the norm of echocardiographic parameters. <i>Sibirskij Āurnal KliniĀeskoj l ĀksperimentalĒnoy Meditsiny</i> , 2023, 38, 163-171.	0.4	0
450	Associations between long-term averages of metabolic parameters in adulthood and cardiac structure and function in later life. <i>Hypertension Research</i> , 2024, 47, 496-506.	2.7	1

#	ARTICLE	IF	CITATIONS
451	The glycolytic pathway to heart failure. , 2024, , 235-266.		0
452	Long-term outcomes of patients bridged to recovery with venoarterial extracorporeal life support. Perfusion (United Kingdom), 0, , .	1.0	0
453	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials. Current Problems in Cardiology, 2023, , 102167.	2.4	0
454	Cross-sectional associations between questionnaire-measured physical activity and tissue doppler indices of left ventricular diastolic function. BMC Cardiovascular Disorders, 2023, 23, .	1.7	0
455	Improved identification of left atrial enlargement in patients with obesity. International Journal of Cardiovascular Imaging, 0, , .	1.5	0
456	Empagliflozin costâ€“effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction. ESC Heart Failure, 2024, 11, 261-270.	3.1	1
457	Exercise intolerance in heart failure with preserved ejection fraction: Causes, consequences and the journey towards a cure. Experimental Physiology, 0, , .	2.0	0
458	Vitamin D, hypertension, and cardiovascular disease. , 2024, , 567-586.		0
459	Modulating Cardiac Hemodynamics Using Tunable Soft Robotic Sleeves in a Porcine Model of HFpEF Physiology for Device Testing Applications. Advanced Functional Materials, 2024, 34, .	14.9	1
460	Effects of recombinant human brain natriuretic peptide combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock		
461	Effects of beta-blocker withdrawal in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis. PLoS ONE, 2023, 18, e0294347.	2.5	0
462	Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
463	Intrinsic Wave Velocity Propagation: A Novel Parameter for Assessing the Effect of Anthracycline Chemotherapy Agents on Cardiac Diastolic Function in Breast Cancer Patients. Current Medical Science, 0, , .	1.8	0
464	Enhanced central sympathetic tone induces heart failure with preserved ejection fraction (HFpEF) in rats. Frontiers in Physiology, 0, 14, .	2.8	0
465	A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy. Therapeutic Advances in Cardiovascular Disease, 2023, 17, .	2.1	0
466	Impact of SGLT2 inhibitors on quality of life in heart failure across the ejection fraction spectrum: Systematic review and meta-analysis. CJC Open, 2023, , .	1.5	0
468	A Real-World Analysis of New-Onset Heart Failure After Anterior Wall ST-Elevation Acute Myocardial Infarction in the United States. American Journal of Cardiology, 2024, 211, 245-250.	1.6	0
469	Investigating automated regression models for estimating left ventricular ejection fraction levels in heart failure patients using circadian ECG features. PLoS ONE, 2023, 18, e0295653.	2.5	0

#	ARTICLE	IF	CITATIONS
470	Prevalence of "hidden" forms of chronic heart failure. , 2023, 19, 457-468.	0.1	0
471	The effects of long-term changes in metabolic parameters on cardiac remodeling and dysfunction. Hypertension Research, 2024, 47, 816-818.	2.7	0
472	Chapter 1: The Burden of Heart Failure. American Journal of Medicine, 2024, 137, S3-S8.	1.5	0
473	Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development. Nature Communications, 2024, 15, .	12.8	0
474	Circulating sphingolipids and relationship to cardiac remodelling before and following a low-energy diet in asymptomatic Type 2 Diabetes. BMC Cardiovascular Disorders, 2024, 24, .	1.7	0
475	Dapansutril Ameliorates Atrial Inflammation and Vulnerability to Atrial Fibrillation in HFpEF Rats. Heart Lung and Circulation, 2024, 33, 65-77.	0.4	0
476	Impaired cardiopulmonary baroreflex function and altered cardiovascular responses to hypovolemia in patients with heart failure with preserved ejection fraction. Journal of Applied Physiology, 2024, 136, 525-534.	2.5	0
477	Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach. International Journal of Molecular Sciences, 2024, 25, 794.	4.1	1
478	Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis. European Heart Journal Cardiovascular Imaging, 2024, 25, 687-697.	1.2	0
479	Clinical characteristics and prognosis of patients with hypertrophic cardiomyopathy and heart failure with preserved ejection fraction. Clinical Research in Cardiology, 2024, 113, 761-769.	3.3	0
480	Study the relationship between left atrial (LA) volume and left ventricular (LV) diastolic dysfunction and LV hypertrophy: Correlate LA volume with cardiovascular risk factors. Disease-a-Month, 2024, 70, 101675.	1.1	0
481	Multifactorial risk factors for hospital readmissions among patients with symptoms of advanced heart failure. ESC Heart Failure, 2024, 11, 1144-1152.	3.1	0
482	Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction. JAMA Network Open, 2024, 7, e2353244.	5.9	0
483	Prognostic value of the fibrinogen-to-albumin ratio (FAR) in patients with chronic heart failure across the different ejection fraction spectrum. Libyan Journal of Medicine, 2024, 19, .	1.6	0
484	High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT. International Journal of Cardiology, 2024, 402, 131818.	1.7	0
485	The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction" A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Heart Lung and Circulation, 2024, 33, 197-208.	0.4	0
486	miR-590-3p Overexpression Improves the Efficacy of hiPSC-CMs for Myocardial Repair. JACC Basic To Translational Science, 2024, , .	4.1	0
487	Back to the basics: The need for an etiological classification of chronic heart failure. Current Problems in Cardiology, 2024, 49, 102460.	2.4	0

#	ARTICLE	IF	CITATIONS
488	Noninvasive Prediction of Pulmonary Capillary Wedge Pressure in Patients With Normal Left Ventricular Ejection Fraction: Comparison of Cardiac Magnetic Resonance With Comprehensive Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2024, 37, 486-494.	2.8	0
489	An evaluation of a service expansion to include patients with heart failure with preserved ejection fraction. <i>British Journal of Cardiac Nursing</i> , 2024, 19, 1-10.	0.1	0
490	Heart failure with preserved ejection fraction: everything the clinician needs to know. <i>Lancet</i> , The, 2024, 403, 1083-1092.	13.7	0
491	Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF study. <i>European Journal of Heart Failure</i> , 0, , .	7.1	0
492	Association between estrogen replacement therapy and heart failure in postmenopausal women: A systematic review and meta-analysis. <i>Preventive Medicine</i> , 2024, 181, 107909.	3.4	0
493	Both HFpEF and HFmrEF should be included in calculating CHA2DS2-VASc score: A Taiwanese longitudinal cohort. <i>Heart Rhythm</i> , 2024, , .	0.7	0
494	Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon. <i>Journal of Clinical Medicine</i> , 2024, 13, 1375.	2.4	0
495	Blood Pressure Variability and Heart Failure: Pathophysiological and Clinical Aspects. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 67-92.	0.1	0
496	Unmet Needs in Drug Treatment of Heart Failure in Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 409-422.	0.1	0
497	Circadian assessment of heart failure using explainable deep learning and novel multi-parameter polar images. <i>Computer Methods and Programs in Biomedicine</i> , 2024, 248, 108107.	4.7	0
498	Impact of hyperuricemia on 5-year clinical outcomes in patients with critical limb ischemia following percutaneous transluminal angioplasty. <i>Coronary Artery Disease</i> , 2024, 35, 201-208.	0.7	0
499	Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2024, 31, 127-140.	2.2	0
500	Demystifying heart failure with a preserved ejection fraction: what you need to know. <i>British Journal of General Practice</i> , 2024, 74, 103-105.	1.4	0